Lovett Evan Reddick, Executive Director, Emerging Therapeutic Areas at GSK, shared on LinkedIn:
“I’m honored to share that I have joined GSK as Executive Director, Emerging Therapeutic Areas within US Medical Oncology.
This transition comes with deep gratitude. My time at Takeda was extraordinary, not simply because of the work, but because of the people. I had the privilege of working with talented, mission-driven colleagues who cared deeply about patients, science, and one another. I leave with tremendous appreciation for the culture, the teams, and the impact we pursued together.
Oncology has always been personal for me. My mother died from breast cancer, and that loss helped shape the direction of my career. Not because any work could bring her back, but because it created a lasting commitment to help others have more time: more moments, more conversations, and more chances to hug the people they love a little longer. 🤍
As I begin this next chapter at GSK, I’m humbled by the opportunity to support emerging oncology programs and contribute to work that connects early scientific promise with future clinical relevance. That work will require partnership across Medical Affairs, R&D, Commercial, Market Access, field medical teams, external experts, trial investigators, and many others.
I’m grateful for the journey behind me, excited for the challenge ahead, and committed to keeping patients and families at the center of our work.
Here’s to the next chapter: grounded in purpose, partnership, and the hope of helping patients and families have more time together.”
Other articles about GSK on OncoDaily.